55,000 Shares in Stoke Therapeutics, Inc. $STOK Purchased by Privium Fund Management B.V.

Privium Fund Management B.V. acquired a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK) during the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 55,000 shares of the company’s stock, valued at approximately $1,746,000.

A number of other large investors have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Stoke Therapeutics by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock worth $74,351,000 after acquiring an additional 217,616 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Stoke Therapeutics by 21.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock worth $11,053,000 after acquiring an additional 293,072 shares during the period. Polar Capital Holdings Plc increased its holdings in shares of Stoke Therapeutics by 49.8% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company’s stock worth $31,102,000 after acquiring an additional 439,824 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of Stoke Therapeutics by 36.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,227,723 shares of the company’s stock worth $38,968,000 after acquiring an additional 327,451 shares during the period. Finally, MPM Bioimpact LLC increased its holdings in shares of Stoke Therapeutics by 13.8% in the 2nd quarter. MPM Bioimpact LLC now owns 789,698 shares of the company’s stock worth $8,963,000 after acquiring an additional 95,710 shares during the period.

Analyst Ratings Changes

STOK has been the topic of a number of analyst reports. Wolfe Research initiated coverage on shares of Stoke Therapeutics in a report on Monday, February 23rd. They issued an “outperform” rating and a $40.00 price objective on the stock. Canaccord Genuity Group increased their price objective on shares of Stoke Therapeutics from $36.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, March 20th. Guggenheim initiated coverage on shares of Stoke Therapeutics in a report on Thursday, February 5th. They issued a “buy” rating and a $60.00 price objective on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stoke Therapeutics in a report on Friday, April 10th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $39.00 price objective on shares of Stoke Therapeutics in a report on Thursday, March 19th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $41.83.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock opened at $32.96 on Wednesday. The firm has a 50 day simple moving average of $34.46 and a 200-day simple moving average of $32.04. The stock has a market capitalization of $2.05 billion, a PE ratio of -274.64 and a beta of 1.20. Stoke Therapeutics, Inc. has a 12-month low of $8.30 and a 12-month high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Monday, March 16th. The company reported ($0.97) earnings per share (EPS) for the quarter. The company had revenue of $1.40 million during the quarter. Stoke Therapeutics had a negative net margin of 3.73% and a negative return on equity of 2.05%. On average, analysts forecast that Stoke Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Thomas Leggett sold 2,382 shares of the stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total value of $74,651.88. Following the completion of the transaction, the chief financial officer directly owned 10,172 shares in the company, valued at $318,790.48. This trade represents a 18.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Jonathan Allan sold 4,628 shares of the stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total transaction of $145,041.52. Following the completion of the transaction, the general counsel owned 28,836 shares of the company’s stock, valued at $903,720.24. This trade represents a 13.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 69,699 shares of company stock valued at $2,526,714. 9.50% of the stock is currently owned by insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.